Research Article

Urine Bikunin as a Marker of Renal Impairment in Fabry's Disease

Table 2

Urine GAGs/UTI levels and distribution in Fabry’s patients and healthy control subjects.

All patients ( = 24) RD Patients ( = 11) NRD Patients ( = 13) Controls ( = 43) All patients versus Controls ( ) RD Patients versus NRD patients ( )RD Patients versus Controls ( )NRD Patients versus Controls ( )

Uronic acid (μgUA/mg Cr)3.83 1.694.61 1.632.60 0.882.59 1.590.030.0090.0040.99

UTI (%)52.8 20.963.2 18.336.6 12.928.5 17.60.00090.004<0.00010.29
HS (%)20.1 9.117.4 10.024.4 5.630.3 9.30.0030.1130.0020.14
CS (%)27.0 14.419.4 9.039.0 13.241.2 11.90.0040.002<0.00010.70

UTI (μgUA/mg Cr)2.29 1.793.15 1.790.93 0.440.82 0.810.0050.0060.00010.74
HS (μgUA/mg Cr)0.66 0.260.67 0.280.63 0.240.72 0.370.570.770.710.58
CS (μgUA/mg Cr)0.89 0.360.79 0.231.03 0.501.04 0.650.380.180.230.97

GAGs/PGs levels are reported as μg of uronic acid (UA) per mg of creatinine.
UTI, HS and CS levels are calculated from total UA content and relative percentages of each GAG.
RD: renal disease (proteinuria/renal damage); NRD: no-renal disease.
Significant differences are reported in bold ( < 0.05).